Single centre experience with histaglobin as an adjunctive treatment of chronic urticaria: A post marketing surveillance study

---

Original Article

Author Details : Kiran Godse*, Dakshata Tare, Ravi Gawali

Volume : 5, Issue : 3, Year : 2019

Article Page : 243-248

https://doi.org/10.18231/j.ijced.2019.052

Suggest article by email

Get Permission

---

Abstract

Introduction: Chronic urticaria consists of itchy rash on most days for at least six weeks. It is caused
by release of histamine and other mediators from degranulated cutaneous mast cells. Antihistamines, the
current treatment mainstay, do not provide relief in many cases and necessitates the use of adjunctive
treatment. Histaglobin, through the synthesis of histamine-neutralizing antibodies, can serve as an adjunct.
The current study was aimed to evaluate the efficacy and safety of Histaglobin, as adjunctive therapy, in
patients with chronic urticaria.
Materials and Methods: Patients with chronic urticaria were enrolled in this single-centre, prospective
open-label study. Patients were administered 3 injections of Histaglobin (1ml), subcutaneously, at intervals
of 7 days. Efficacy was assessed by grading the change in disease activity, measured using urticarial activity
score (UAS 7) on days 0, 7, 14, 28 and 42. Adverse events (AEs) and concomitant medications were also
recorded at each study visit.
Results: Thirty-seven of the 38 enrolled patients completed study by following-up on day 28. Thirtyfour
(91.9%) patients showed improvement; 21 (56.8%) showed ‘moderate improvement’ and 13(35.1%)
showed ‘clear cut improvement’. There was a significant (p<0> 6.1) to Day 28(6.06.2). There was one patient who developed redness at injection site. Half the patients
on antihistamines and all those on steroid treatment were able to reduce/stop these treatments at the end of
study.
Conclusion: Histaglobin treatment was found to be effective in the treatment of chronic urticaria. It was
also well tolerated and reduced antihistamines and steroids pill burden. Histaglobin, is a safe, well-tolerated
and valuable adjunct to antihistamines in the management of chronic urticaria.

How to cite : Godse K, Tare D, Gawali R, Single centre experience with histaglobin as an adjunctive treatment of chronic urticaria: A post marketing surveillance study. IP Indian J Clin Exp Dermatol 2019;5(3):243-248

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.